Prognostic Role of β-Blocker Selectivity and Dosage Regimens in Heart Failure Patients. Insights from the MECKI Score Database

Abstract

In a large population of chronic HFrEF patients, β-blockers were associated with a more favourable prognosis without any difference between β1- and β2-receptor-blockers vs. β1-selective blockers. A better outcome was observed in subjects receiving a high daily dose.